

HYDRATION, THERAPEUTIC, PROPHYLACTIC, AND DIAGNOSTIC INJECTIONS AND INFUSIONS

ISSUE DATE:

AUTHORITY: 32 CFR 199.4(b)(2)(v), (b)(3)(iii), (b)(5)(v), (d)(3)(vi), (e)(11)(ii), (e)(11)(iii), (g)(15)

I. CPT¹ PROCEDURE CODES

96360 - 96379

II. HCPCS PROCEDURE CODES

J3487, J3488

III. DESCRIPTION

Intravenous (IV) hydration infusion consists of pre-packaged fluid and electrolytes, but not infusion of drugs or other substances. A therapeutic, prophylactic, or diagnostic IV infusion or injection (other than hydration) is for the administration of substances or drugs.

Policy regarding chemotherapy administration is found in [Section 16.3](#).

IV. POLICY

A. Hydration IV infusion consistent of a pre-packaged fluid and electrolytes (e.g., normal saline, D5-1/2 normal saline +30mEq KCl/liter), but are not used to report infusion of drugs or other substances are covered.

B. Intravenous or intra-arterial push (an injection in which the health care professional who administers the substance/drug is continuously present to administer the injection and observe the patient or an infusion of 15 minutes or less) for therapy, prophylactic, or diagnosis is covered.

C. Off-label use of zoledronic acid (Zometa®) for treatment of breast cancer may be cost-shared when:

1. Patient was premenopausal at the time of diagnosis, and has stage I or II breast cancer;

¹ CPT only © 2006 American Medical Association (or such other date of publication of CPT). All Rights Reserved.

TRICARE POLICY MANUAL 6010.54-M, AUGUST 1, 2002

CHAPTER 7, SECTION 2.8

HYDRATION, THERAPEUTIC, PROPHYLACTIC, AND DIAGNOSTIC INJECTIONS AND INFUSIONS

2. Patient has had surgically induced menopause (e.g., oophorectomy) or has been put temporarily into menopause (chemically induced menopause with Goserelin or similar product) prior to administration of zoledronic acid;

3. Patient has hormone receptor (Estrogen Receptor (ER) and/or Progesterone Receptor (PR)) positive disease and zoledronic acid is being used in combination with hormonal therapy (e.g., Tamoxifen, Arimedex®, Aromasin®, Femara®);

4. No concurrent adjuvant chemotherapy has been given or planned;

5. Prescriber is an oncologist or an individual highly familiar with prescribing and monitoring of oncology-related medications.

V. EFFECTIVE DATE

February 12, 2009 for off-label use of zoledronic acid (Zometa®) for treatment of breast cancer.

- END -